Provided by Tiger Trade Technology Pte. Ltd.

Ovid Therapeutics Inc.

1.58
-0.0200-1.25%
Pre-market: 1.600.0200+1.27%09:09 EST
Volume:776.51K
Turnover:1.23M
Market Cap:205.69M
PE:-3.13
High:1.61
Open:1.59
Low:1.54
Close:1.60
52wk High:2.01
52wk Low:0.2425
Shares:130.18M
Float Shares:59.52M
Volume Ratio:0.41
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5047
EPS(LYR):-0.3663
ROE:-60.06%
ROA:-29.33%
PB:4.60
PE(LYR):-4.31

Loading ...

Both retail investors who control a good portion of Ovid Therapeutics Inc. (NASDAQ:OVID) along with institutions must be dismayed after last week's 11% decrease

Simply Wall St.
·
Jan 30

Ovid Therapeutics Unveils Pipeline Advances Targeting Drug-Resistant Epilepsy and Neuropsychiatric Disorders

Reuters
·
Jan 13

Ra Capital Management, L.p. Reports 9.9% Passive Stake in Ovid Therapeutics as of Dec 11 - SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

BRIEF-Ovid Therapeutics Announces Phase 1 Results For Ov350

Reuters
·
Dec 18, 2025

Ovid Therapeutics Showcases Neurotherapeutics Pipeline Targeting Neural Hyperexcitability

Reuters
·
Dec 18, 2025

Ovid Therapeutics Inc - Ov350 Shows Good Safety Profile Supporting Kcc2 Portfolio Advancement

THOMSON REUTERS
·
Dec 18, 2025

Ovid Therapeutics Inc - Announces Phase 1 Results for Ov350

THOMSON REUTERS
·
Dec 18, 2025

Ovid Therapeutics Inc - No Treatment-Related Safety Findings or Serious Adverse Events

THOMSON REUTERS
·
Dec 18, 2025

Ovid Therapeutics Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071

Reuters
·
Dec 18, 2025

Ovid Therapeutics Inc. Held Special Shareholder Meeting

Reuters
·
Dec 12, 2025

Ovid Therapeutics Names Dr. Petra Kaufmann as Chief Medical Officer

Reuters
·
Dec 02, 2025

Ovid Therapeutics Appoints DR. Petra Kaufmann as Chief Medical Officer

THOMSON REUTERS
·
Dec 02, 2025

Ovid Therapeutics Showcases Neurotherapeutics Pipeline Targeting Drug-Resistant Seizures and Neural Hyperexcitability

Reuters
·
Nov 14, 2025

BTIG Keeps Their Buy Rating on Ovid Therapeutics (OVID)

TIPRANKS
·
Nov 14, 2025

Ovid Therapeutics Q3 revenue slightly beats expectations

Reuters
·
Nov 12, 2025

Ovid Therapeutics reports Q3 revenue of $132,000 and R&D expenses of $5.9 million

Reuters
·
Nov 12, 2025

BRIEF-Ovid Therapeutics Q3 EPS USD -0.17

Reuters
·
Nov 12, 2025

Ovid Therapeutics Names Meg Alexander as CEO

Reuters
·
Nov 12, 2025

Ovid Therapeutics Q3 Revenue USD 132 Thousand VS. Ibes Estimate USD 153.3 Thousand

THOMSON REUTERS
·
Nov 12, 2025

Ovid Therapeutics Inc - Jeremy M. Levin to Transition to Executive Chair of Bod

THOMSON REUTERS
·
Nov 12, 2025